Nanox Collaborates with Leading Czech Medical Imaging Distributor EXRAY to Expand European Footprint

Rhea-AI Summary

NANO-X IMAGING (Nasdaq: NNOX) on November 6, 2025 announced a distribution agreement with Czech imaging distributor EXRAY to introduce the Nanox.ARC multi-source digital tomosynthesis system across the Czech Republic.

EXRAY, founded in 2013, has installations in >50% of the country’s ~200 healthcare facilities and will lead market introduction, sales and service. The Nanox.ARC holds a CE Mark clearance for commercialization across the European Union.

Positive

• CE Mark clearance enables EU commercialization
• EXRAY has installations in 50%+ of ~200 Czech healthcare facilities
• Signed distribution agreement gives national sales & service coverage in Czech Republic
• Partnership targets university, public and private hospital networks for clinical validation

Negative

• None.

Insights

Market Expansion Analyst

Strategic distribution deal gives Nanox direct commercial access to Czech hospitals via EXRAY's large installed base.

Under the agreement, NANO-X IMAGING LTD will have EXRAY lead sales, market introduction and service for the Nanox.ARC, a CE‑marked multi‑source digital tomosynthesis system, across the Czech Republic starting from the announced Nov 06, 2025 arrangement.

EXRAY reports installations in more than half of the country’s 200 healthcare facilities and claims > 50%+ market penetration, implying immediate access to established relationships with university hospitals, public hospitals and private clinic networks that can accelerate adoption without Nanox building a local sales force.

Key dependencies and risks include EXRAY’s execution on training, service quality and clinical validation efforts that it will provide; regulatory clearance is already in place in the EU for the device, so commercialization hinges on partner performance and local purchasing cycles. Watch adoption signals and any concrete clinical validation outcomes over the next 6–18 months to gauge commercial traction.

EXRAY, leading Czech radiography supplier with 50%+ market penetration, to distribute Nanox’s imaging solutions 

PETACH TIKVA, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced a distribution agreement with EXRAY s.r.o (“EXRAY”), a leading Czech distributor of medical imaging systems, to introduce Nanox’s advanced imaging solutions to healthcare providers across the Czech Republic.

Under the terms of the agreement, EXRAY will lead the market introduction, sales and service of Nanox’s medical imaging solution, the Nanox.ARC, a multi-source digital tomosynthesis system that utilizes advanced 3D imaging technology to provide enhanced diagnostic capabilities at a lower cost than traditional systems. Following its CE Mark certification, the Nanox.ARC is cleared for commercialization across the European Union.

Founded in 2013, EXRAY is recognized as the number one supplier of digital radiography systems in the Czech Republic, with installations in more than half of the country’s 200 healthcare facilities and nationwide sales and service coverage.

“Partnering with EXRAY represents a significant milestone in our European expansion. Our collaboration will leverage EXRAY’s strong relationships with university hospitals, public hospitals and private clinic networks to expand access to high-quality, affordable imaging services for patients in the Czech Republic,” said Erez Meltzer, CEO and Acting Chairman of Nanox. “We look forward to working with the EXRAY team, whose established market presence and technical expertise position them as an ideal partner to introduce our comprehensive imaging platform and provide clinical validation to further demonstrate the benefits of our imaging technology.”

Jan Hamadej, CEO of EXRAY, said, “We are proud to partner with Nanox and bring this innovative imaging solution to the Czech market. Our long-standing relationships with hospitals and clinics, together with Nanox’s advanced imaging system, will allow us to offer new options for improving diagnostic capabilities and patient outcomes across the country.”

About Nanox

Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by bringing a full solution of affordable medical imaging technologies based on advanced AI and proprietary digital X-ray source.

Nanox's vision encompasses expanding the reach of Nanox technology both within and beyond hospital settings, providing a seamless end-to-end solution from scan to diagnosis, leveraging AI to enhance the efficiency of routine medical imaging technology and processes, in order to improve early detection and treatment and maintaining a clinically driven approach. The Nanox ecosystem includes Nanox.ARC – a multi-source digital tomosynthesis system that is cost-effective and user-friendly; Nanox.AI LTD – an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic diseases; Nanox.CLOUD – a cloud-based software platform that manages and stores data collected by Nanox devices, and provides users with tools for in-depth imaging analysis; Nanox.MARKETPLACE – a proprietary decentralized marketplace through Nanox’s subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts, and a comprehensive teleradiology services platform. By improving early detection and treatment, Nanox aims to enhance better health outcomes worldwide. For more information, please visit www.nanox.vision

Forward-Looking Statements

This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (iv) Nanox’s ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (v) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vi) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (vii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; (viii) Nanox’s ability to conduct business globally; (ix) changes in global, political, economic, business, competitive, market and regulatory forces; (x) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xi) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things; and (xii) potential litigation associated with our transactions.

For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations.

Contacts

Media Contact:
Ben Shannon
ICR Healthcare
NanoxPR@icrinc.com

Investor Contact:
Mike Cavanaugh
ICR Healthcare
mike.cavanaugh@icrhealthcare.com

FAQ

What did NNOX announce on November 6, 2025 about the Czech Republic?

NNOX announced a distribution agreement with EXRAY to sell and service the Nanox.ARC across the Czech Republic.

Does the Nanox.ARC have regulatory clearance for Europe for NNOX?

Yes. The Nanox.ARC holds a CE Mark clearance for commercialization across the European Union.

What is EXRAY’s market reach for NNOX’s Czech distribution?

EXRAY reports installations in more than 50% of the country’s ~200 healthcare facilities and nationwide sales and service coverage.

Will EXRAY provide service and clinical validation for NNOX devices in Czech hospitals?

Yes. EXRAY will lead market introduction, sales and service and work with hospital networks to provide clinical validation.

How does the NNOX–EXRAY deal affect access to imaging in Czech Republic?

The agreement aims to expand access by deploying the Nanox.ARC through EXRAY’s existing university, public, and private clinic relationships.